• Explore /
  • Poster
  • / A phase 2/3 trial of oral azacitidine (Oral-AZA) in patients (pts) with low- or intermediate-risk myelodysplastic syndromes (MDS).

A phase 2/3 trial of oral azacitidine (Oral-AZA) in patients (pts) with low- or intermediate-risk myelodysplastic syndromes (MDS).

Abstract Poster

Authors

null

Guillermo Garcia-Manero

MD Anderson Cancer Center, Houston, TX

Guillermo Garcia-Manero , Valeria Santini , Pierre Fenaux , Takahiro Suzuki , Mikkael A. Sekeres , Jun He , Ronit Barkalifa , Carlos Enrique Vigil , Thomas Prebet , Rami S. Komrokji , Aristoteles Giagounidis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myelodysplastic Syndromes (MDS)

Clinical Trial Registration Number

NCT05469737

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS7083)

DOI

10.1200/JCO.2023.41.16_suppl.TPS7083

Abstract #

TPS7083

Poster Bd #

208a

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results.

RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results.

First Author: Mrinal M. Gounder

First Author: Kristine Peregrino Lacuna

First Author: James Yuhtyng Chen

First Author: Amer Methqal Zeidan